HilleVax, Inc. (HLVX)
| Market Cap | 323.24M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -102.41M |
| Shares Out | 33.43M |
| EPS (ttm) | -3.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 220,392 |
| Open | 9.83 |
| Previous Close | 10.11 |
| Day's Range | 8.82 - 10.06 |
| 52-Week Range | 8.82 - 20.95 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About HLVX
HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Our initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. It is estimated that norovirus causes nearly 700 million cases of illness and more than 200,000 deaths worldwide per year, as well as significant additional economic and social burden. To date, HIL-214 has been studied in nine clinical trials conducted...
Financial Performance
Financial StatementsNews
HilleVax Announces Pricing of Upsized Initial Public Offering
HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the pricing of its upsized initial public offering...
Norovirus vaccine developer HilleVax files for a $100 million IPO
HilleVax, a Phase 2 biotech developing a novel norovirus vaccine in-licensed from Takeda, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.
HilleVax IPO Registration Document (S-1)
HilleVax has filed to go public with an IPO on the NASDAQ.